Histological outcome during long-term lamivudine therapy Jules L. Dienstag, Robert D. Goldin, E.Jenny Heathcote, H.W.L. Hann, Mary Woessner, Sally L. Stephenson, Stephen Gardner, D.Fraser Gray, Eugene R. Schiff  Gastroenterology  Volume 124, Issue 1, Pages 105-117 (January 2003) DOI: 10.1053/gast.2003.50013 Copyright © 2003 American Gastroenterological Association Terms and Conditions

Fig. 1 Study design showing the timing of biopsies and YMDD-variant HBV assessments. Gastroenterology 2003 124, 105-117DOI: (10.1053/gast.2003.50013) Copyright © 2003 American Gastroenterological Association Terms and Conditions

Fig. 2 Change in necroinflammatory scores for all 3 biopsies for individual patients according to duration of YMDD-variant HBV. The panels on the left represent a comparison between the pretreatment biopsy and the biopsy obtained at the end of 12 months of randomized treatment; the panels on the right represent a comparison between the end-of-randomized treatment biopsy and the month-24 biopsy. Gastroenterology 2003 124, 105-117DOI: (10.1053/gast.2003.50013) Copyright © 2003 American Gastroenterological Association Terms and Conditions

Fig. 3 Improvement in bridging fibrosis during lamivudine therapy—photographs (A) before (pre) and (B) after (post) therapy (patient with YMDD-variant HBV). Gastroenterology 2003 124, 105-117DOI: (10.1053/gast.2003.50013) Copyright © 2003 American Gastroenterological Association Terms and Conditions

Fig. 4 Improvement in cirrhosis during lamivudine therapy—photographs (A) before (pre) and (B) after (post) therapy (patient with wild-type HBV). Gastroenterology 2003 124, 105-117DOI: (10.1053/gast.2003.50013) Copyright © 2003 American Gastroenterological Association Terms and Conditions